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ABSTRACT 
 
Standardization of a Pan-Specific Test for the Diagnosis of Lyme Disease in Veterinary 
Medicine. (May 2012) 
 
Erin Mcgregor 
Department of Veterinary Medicine and Biomedical Sciences 
Texas A&M University 
 
Research Advisor: Dr. Maria Esteve-Gassent 
Department of Veterinary Pathobiology  
 
Lyme disease (LD) is the most prevalent tick borne disease in the US with a total of 
22,572 confirmed human cases reported to CDC in 2010. LD is caused by the infection 
of a mammalian host with the bacterial pathogen Borrelia burgdorferi, through the bite 
of an infected tick.  Currently, there is no pan-specific test available for the diagnosis of 
the disease. Our hypothesis is that a non-species specific competitive ELISA test, also 
known as pan- specific ELISA test, will help improve the diagnosis of LD not only in 
Veterinary Medicine but will also help evaluating the sero-prevalence of this disease in 
different species of animals.  Our objectives for this project are to 1) evaluate the 
antibody level against B. burgdorferi whole cell lysates and the Borrelial recombinant 
proteins P66 and OspC of a collection of dog serum samples by traditional ELISA and 2) 
determine the immune-reactivity of Texan dogs serum samples to Borrelia by 
Immunoblot assay, so as to determine the cut off values for the ELISA assay, This 
evaluation will help establish the basic parameters for the final competitive ELISA and 
will determine the validity of P66 as potential antigen to be use in the final assay.  We 
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will achieve our objectives by i) purification of OspC and P66 ii) evaluate the immune 
reactivity of the serum collection to P66 and OspC and Borrelia whole cell lysates by 
ELISA and by Immunoblot and iii) designate the starting conditions of the competitive 
ELISA for diagnostics of Lyme disease.  It has been concluded that IFA is not an 
effective testing method because of the high volume of false negatives that are 
associated with it.  By performing Western Blots and ELISAs as confirmatory tests, the 
number of cases being reported will increase because of the decrease in false negatives, 
thus allowing for surveillance of the disease to increase. 
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NOMENCLATURE 
 
LD Lyme disease 
EM Eythema migrans 
rOspC Recombinant uter embrane protein C 
Amp Ampicillin 
Kan Kanamycin 
PASN Post absorption supernatants 
ELISA Enzyme linked immuno sorbed assay 
BSA  Bovine serum albumin 
PBS Phosphate buffer saline 
ROC Receiving operating characteristic  
WB Western blot 
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CHAPTER I 
INTRODUCTION 
Lyme disease (LD) is a vector borne disease, meaning it is transmitted from an insect to 
a human or other animal. It is the most common vector borne disease in North America, 
with a total of 22,572 confirmed human cases reported to CDC in 2010.  LD is caused by 
infection of mammalian host with the bacteria Borrelia burgdorferi acquired through the 
bite of an infected Ixodes tick (2, 11, 14, 22, 28).  Currently there is very limited 
epidemiological data available to represent the number of confirmed animal cases 
nationwide (5) since Lyme disease is not an animal reportable disease. Therefore the 
epidemiological data available come from studies done nationwide in collaboration with 
pharmaceutical companies and using their commercially available kits (5).  In 2010, out 
of 500 LD tests performed at TVMDL, 40% of the positive tests were from Texas while 
the other 60% were from out of state.  There were 69 positive animal cases that were 
confirmed for Lyme, and occurred mostly in East Texas.  When analyzing the confirmed 
number of human cases in Texas over the last 10 years (personal communication from 
Texas State Department of Health Services), most of them occurred in the metropolitan 
areas of East Texas.  There have also been several human cases reported in Western 
Texas and near the panhandle, where few to no animal cases have been reported.  The 
lack of information and awareness of LD in rural areas and a better understanding in the 
_______________ 
This thesis follows the style of Infection and Immunity. 
  2 
 
metropolitan areas could explain the reporting differences between the two areas. 
Consequently, by developing surveillance programs in the State of Texas, we could 
determine which are areas of high risk for this disease by determining the sero-
prevalence in the wildlife together with the detection of Borrelia burgdorferi DNA in 
sampled ticks (4, 7, 13, 18, 19, 24).  
 
 
 
 
 
FIG 1. Tick Life Cycle. Infectious cycle of the European Borrelia burgdorferi sensu lato 
genospecies B. burgdorferi sensu lato is the only pathogenic genospecies present in the US and 
Europe, both rodents and birds are reservoirs. A red cross indicates a non-reservoir host. 
(Adapted from “Lyme borreliosis” Stanek G) 
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Carriers, signs and symptoms 
Lyme disease is a very common problem in several regions around the world (22).  
Lyme disease is transmitted by the bite of Ixodes ticks.  I. scapualaris is the competent 
vector for the transmission of LD in East US while I. pacificus is mostly associated with 
the transmission of the disease in Western US (32). Furthermore, I. ricinus will be the 
competent vector transmitting the disease in Euroasia.   The regions mostly affected by 
LD have similar environmental conditions that allow ticks to thrive (1).                       
The life and transmission cycle of a tick begins when a fully developed female tick drops 
off the host and lays eggs (FIG. 1).  Once the eggs hatch the larval stage of the tick seeks 
a new host, these larvae are not infected with the infectious Borrelia responsible of LD, 
and they acquire it after feeding on an infected small mammal, usually a small rodent.  
After feeding on the first host, the larvae drop to ground and develop into the nymph 
stage.  The nymph then attaches to the second host and feeds.  At this point, nymphs can 
infect larger animals, including humans, dogs, horses, deer, etc. The nymph molts to an 
adult, attaches to the third and final host and feeds (FIG 1).  LD can be transmitted to 
any of these hosts (23).  In North America, the only species of Lyme borrelia known to 
cause human disease is Borrelia burgdorferi sensu stricto.  In Europe, there are at least 
five species of Lyme borrelia (B. afzelii, B. garinii, B. burgdorferi, B. spielmanii, and 
B.a bavariensis) that can cause the disease, thus leading to a wider variety of possible 
clinical manifestations in Europe than in North America. B afzelii and B garinii 
infections account for most Lyme borreliosis cases in Europe, whereas B garinii is 
predominant in Asia.  Moreover, B afzelii is mostly associated with skin manifestations, 
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B garinii seems to be the most neurotropic, and B burgdorferi seems to be the most 
arthritogenic.(1).                                                                                                                
LD is characterized by various neurological, dermatological, cardiovascular and 
musculoskeletal problems. (30, 34)  These symptoms can vary by region.  For example, 
arthritis is more common in American patients while neuroborreliosis is more common 
in European patient. Erythema migrans (EM) is the only way to characterize Lyme 
without a diagnostic test (1). EM is a red, “bulls-eye” shaped rash that appears on some 
patients infected with Lyme. Only 68% of the US patients develop this symptom and 
therefore better understanding of the distribution of the pathogen in different areas of the 
country will eventually improve the awareness of the disease in the population and the 
medical community. The symptoms of the disease also differ based on the stage of the 
disease (2, 3, 10, 14).  The first stage, early-localized stage, occurs between 1-4 weeks 
after infection.  During this stage, patients may experience flu-like symptoms, in 
addition to the development of EM.  The second stage, early disseminated, extends 
from 1 to 4 months after the infection has occurred.  Additional rashes, partial paralysis, 
conjunctivitis, inability to concentrate and other flu-like symptoms characterize the 
stage.  The final stage, late disseminated or Chronic Lyme disease, can be developed 
after a few months to a few of the establishment of the infection.  During this stage, the 
disease can cause severe damage to the joints, nerves and brain.  Inflammation, severe 
fatigue, partial nerve paralysis, neurological problems and chronic arthritis also 
accompany this stage of LD.  Consequently, by establishing surveillance programs with 
a better diagnostic tool, the time at which the diagnosis of the disease is done will 
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significantly impact the success of the disease treatment the patients will receive (1). 
Moreover, surveillance programs will help introducing awareness campaigns in the local 
and medical population, increasing the early diagnostic of the disease and the prevention 
of tick bites by an informed society (4, 7). 
Various testing methods 
With EM being the only physical characteristic of Lyme disease, accurate testing 
methods are very important when it comes to diagnosing the disease. There are various 
laboratory-testing methods, which include: culturing of bacterial pathogen from biopsy 
samples, PCR from biopsy or from blood (serum and/or plasma), serolocial tests such as 
ELISA (enzyme immunoassay), IFA (immunofluorescent-antibody assay) and Western 
Blot (immunoblot, IB) (1).  The commercially available serological diagnostic kits are 
very expensive and mostly detect chronic cases with clinical signs, but are not efficient 
in detecting acute and/or subclinical cases (15, 25, 27, 29, 33, 34).  Currently, there are 
also no reliable tests to detect the causative agent of the disease.  PCR has been proven 
to be the most effective of these methods (1, 26, 34); however, it isn’t used as often as 
other methods due to the lengthy process and the fact that it is only giving valuable 
information when biopsy tissue is used. Culture methods from blood, serum and/or 
plasma are very rarely used because of limitations when it comes to isolate the bacterium 
from these samples. ELISA and IB have very close testing sensitivities, but IB is more 
specific. These two methods are used more often in the diagnostic laboratory than PCR. 
Variations among these tests have both advantages and disadvantages. Many companies 
today are trying to develop new and improved methods that are more specific and 
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sensitive than the methods mentioned above (5, 33).  With Lyme disease being such a 
common disease it is imperative to find an effective and efficient method to diagnose 
those infected with the disease. The Lyme serological diagnostics techniques mostly 
used in veterinary medicine are the IFA and the ELISA test using the C6 epitope of the 
variable surface antigen VlsE. The IFA is known for its subjective interpretation and its 
low sensitivity, while the ELISA C6 test is known for it high sensitivity (9, 16, 21). 
Nevertheless, there are limitations to all this tests like the fact that each one uses species-
specific antibodies and they can detect animals infected for at least 3 weeks to up to 6 
months. Consequently we foresee the necessity for better diagnostic test that can be used 
in sero-surveillance programs to control and prevent Lyme disease.  
Hypothesis 
Our hypothesis is that a non-species specific competitive ELISA test, also known as pan-
specific ELISA test, will help improve the diagnosis of Lyme disease in both human and 
veterinary medicine.  More over, this type of test will help in the establishment of 
surveillance programs in which a number of different animal species can be tested 
without the development of a significant number of specific reagents. Our objectives for 
this project is to 1) evaluate the antibody level against B. burgdorferi whole cell lysates 
and the Borrelial recombinant proteins P66 and OspC of a collection of dog serum 
samples by traditional ELISA and 2) determine the immune-reactivity of Texan dogs 
serum samples to Borrelia by Immunoblot assay, so as to determine the cut off values for 
the ELISA assay. This evaluation will help establishing the basic parameters for the final 
competitive ELISA and will determine the validity of P66 as potential antigen to be use 
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in the final assay. The immune-reactivity to OspC will help us determine which animals 
in the population studied are in the early stages of Lyme and whether or not the sero-
reactivity towards P66 can be used to detect animals with Lyme disease regardless of the 
stage of infection in which they are.  
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CHAPTER II 
 
METHODS 
 
The methods described below are used for the preparation and usage of both 
recombinant proteins P66 (rP66) and OspC (rOspC) together with the standardization of 
specific ELISA and Immunoblot tests utilized to evaluate dog and deer samples for LD.   
 
Protein expression and purification 
Protein induction 
Both rP66 and rOspC were previously cloned (Dr. Esteve-Gassent, unpublished data) in 
the expression vector pET23aTM (Novagen) and in the expression E. coli RosettaTM 
strain (Novagen).  The first step to purify the rP66 and rOspC was to induce their 
expression in E. coli. To this end, a culture of the expression host E. coli strain 
RosettaTM encoding rP66 or rOspC were started in LB broth media containing ampicillin 
100µg/ml (Amp100) and chloramphenicol 20µg/ml (Can20) at 37ºC, shaking overnight.  
A 1:100 dilution of each of the cultures were used to start 1 liter of LB Broth containing 
Amp100  and Can20. Large cultures were shaken for 4-5 hours at 37ºC or until 
OD600nm=0.5 to 0.8.  Then, the expression of the recombinant protein was induced by 
adding 1 ml of Isopropyl β-D-1-thiogalactopyranoside (IPTG) to the cultures, and 
continue shaking for 2 hours at 37°C.  After the 2 h induction, cells were harvested by 
centrifugation for 20 minutes at 4000 rpm and 4ºC.  Pellets were stored at -80ºC until 
use. 
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Protein purification 
After thawing on ice the pellets of RosettaTM cells expressing either rP66 or rOspC, 25 
ml of Lysis Buffer (50mM sodium phosphate, 8 M urea, 300 mM NaCl, 20 mM 
imidazole pH 7.4) was added to resuspend the cells. Cells were disrupted by utilizing a 
French press (Thermo scientific). Each pellet was French pressed 3 times to ensure 
complete lysis of the cells. After the French Press, lysates were centrifuged for 20 
minutes at 4000 rpm and 4ºC.  Pellets were saved at -80°C until purification of the 
protein was confirmed.  Supernatants were mixed with 5 ml of Nickle beads (His60 
SuperflowTM resin, Chlontech) previously equilibrated with Wash Buffer (50mM sodium 
phosphate, 8 M urea, 300 mM NaCl, 40 mM imidazole pH 7.4) and incubated overnight 
at 4°C with continuous gentle shaking.  After the overnight binding, beads were clean by 
centrifugation for 5 minutes at 500 rpm and 4ºC to remove any unspecific binding. Post 
absorption supernatants (PASN) and washing fraction were saved at -80ºC until 
purification of each recombinant protein was confirmed. Beads with the recombinant His 
tag containing proteins were allowed to pack at room temperature in a chromatography 
column (BioRad). While the beads settle, two sets of 25 elution collection tubes were 
prepared.  (Tubes should be labeled E1-E25).  Each one of the proteins was eluted by 
adding 10 ml of the elution buffer (50mM sodium phosphate, 8 M urea, 300mM NaCl, 
300mM imidazole pH 7.4) to the column. Approximately 20 ml of elution buffer was 
needed to ensure the adequate purification of the recombinant proteins. Fifty µl of each 
elution fraction was combined with 50 µl of 2X Final Sample Buffer (2x FSB) to check 
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for the fraction in which the recombinant protein eluted.  Elution fractions were saved at 
-80°C until use in the ELISA assays.    
 
SDS-PAGE gel 
In order to determine in which elution fractions the recombinant proteins were mostly 
present, an aliquot of the induction pellet, PASN, wash fractions and elution fractions 
were separated in a 12% SDS-PAGE gel. Gels were stained in Coomassiee Blue (0.25% 
cooomassiee brilliant blue dye R250, 45% methanol, 10% acetic) for 1 hr at room 
temperature. After destaining (45% methanol, 10% acetic acid), the more concentrated 
elution fractions were selected and prepared for purification. The gels were stored (10% 
ethanol, 5% glycerol) and dried for further reference. 
 
Protein clean up and concentration 
The fractions containing the recombinant proteins were cleaned and concentrated by 
using the Amicon filtration system (Millipore) with cut off pores of 3kDa or 5kDa to 
ensure the retention of the proteins of interest. The concentrated protein was further 
cleaned by dialysis to ensure the elimination of the denaturing agent Urea and the 
Imidazol used to elute the protein during the purification steps. To this end, the fractions 
being cleaned are placed in a dialysis cassette (Slide-A-Lyser® Cassette, Thermos 
Scintific) and in 500ml of dialysis buffer (50mM sodium phosphate, 300mM NaCl) for 2 
hours at room temperature and continuous stiring.  After 2 hours, the concentrated 
fractions were recovered and stored at -80°C. Aliquots were used to determine protein 
concentration.  
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Protein quantification 
Protein concentrations was determined by using the Pierce BSA Assay Kit (Thermo 
Scientific) so as to adjust the protein concentration to the one needed to run the ELISA 
test. Briefly, BSA (Bovine Serum Albumin) protein standards were made with 
concentrations ranging from 0 to 250µg/ml.  The test proteins were diluted 1:5 and 1:10 
and 25µL of each protein dilutions and standards were placed in triplicates in a 96 well 
plate (Corning). After adding 200 µl of the Working reagent plates were incubated for 30 
minutes at 37ºC and in the dark. After incubation, protein concentration was measured in 
a plate reader (BMI LABTECH OMEGA) and protein aliquots adjusted to the right 
concentrations for the ELISA test. 
 
Enzyme linked immuno sorbed assay 
To determine the level of specific antibodies in the dog sera (samples were obtained 
from TVMDL years 2011-2012) to B. burgdorferi lysates, rP66 and rOspC Enzyme 
Linked Immunosorbed Assays (ELISA) were done. To this end, 96 well plates (Nunc, 
Thermo Scientific) were coated with the appropriate antigen at a concentration of 
500ng/well (rP66 and rOspC) and 107 cells/well (B. burgdorferi lysate) in carbonate 
buffer pH 9.4 at 4ºC overnight. After coating, plates were washed three times with 
Phosphate Buffer Saline containing 0.5% Tween 20 (PBS-T). Plates were then blocked 
with 200µL of PBS containing 3% BSA at 4ºC overnight. After blocking, plates were 
washed three times in PBS-T and incubated for 1hr with serial two-fold dilutions ranging 
from 1:400 to 1:25,600 of each of the animal samples in PBS-T containing 1% BSA. No 
sample serum was used as the blank. After washing the plates 3 times with PBS-T, 
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1:2,000 dilution of the anti-dog HRP- conjugated IgG antibody was added to each well.  
The plates were shaken for 1 hour at room temperature.  The plates were then washed 3 
times in PBS-T and incubated with 100µl/well of the OPD buffer (Thermo Scientific), 
for 30 minutes in the dark (in a drawer wrapped in foil). Plates were read at a 
wavelength of 450nm and analyzed by using the BMI LABTECH OMEGA computer 
program and plate reader.  
 
Western blot  
The Western Blots were done following the Trinity Biotech B. burgdorferi MarblotTM 
Strip Test System.  Briefly, remove the number of strips (coated with B. burgdorferi 
antigen) with blunt forceps.  For each sample or control strip (Positive, Negative and 
weakly reactive) a channel in a 12-strip plate was filled with 2 ml of 1X sample 
Diluent/wash Solution (tris buffered saline) provided in the kit. After strips were 
equilibrated for 5 minutes, 20 µL of each of the samples were added to the appropriately 
marked channel and incubated at room temperature for 30 minutes. Strips were washed 
three times by adding 2 mL of sample Diluent/Wash Solution to each channel of the strip 
incubation tray and incubated for 5 minutes shaking. Two mL of 1:2,000 dilution of the 
anti-dog AP conjugated IgG antibody was added to each strip containing well and 
incubated for 30 minutes at room temperature.  Strips were then washed three times and 
2 mL of Color Developing Solution was added to each channel.  All strips were 
incubated for 6 minutes to allow color development. Strips were then washed with 2 mL 
of deionized water, air-dried and evaluated. For the evaluation, we considered positive 
strips that show 3 or more bands in the region bellow the 40kDa band and 2 or more 
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bands in the region between 91kDa and 45kDa bands. A group of 13 negative dog 
samples (puppies from an in-house dog colony) were used to determine the evaluation 
criteria.  
 
Statistical methods 
Continuous variables will be described by median and interquartile range (IQR) or mean 
and standard deviation.  The dichotomous variables were described by the number and 
percent positive (1) and negative (0). Logistic regression models were used to estimate 
the probability of a positive result as a function of antibody levels.  These probabilities 
were used in a Receiver Operating Characteristic (ROC) analysis to determine the 
optimum antibody level cut-off for diagnosis that maximize the proportion correctly 
classified.  Antibodies were compared for their ability to classify by performing a test of 
equality of ROC areas. All data manipulation and statistical analysis was performed in 
Stata (31). 
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CHAPTER III 
RESULTS 
 
 
Protein purification 
 
SDS-PAGE gel 
After growing the bacterial clone expressing each of the recombinant proteins we 
induced their expression for 2hrs at 37ºC. Once the induction was terminated, cells were 
disrupted by French Press and recombinant proteins were purified utilizing their binding 
to Ni chromatography through the 6*His tag engineered in their C terminus end. Each 
one of the eluted fractions together with the induction lysate and the post-absortion 
supernatant (resulting from the binding of the recombinant proteins to the Ni beads) 
were separated in a 12% separating SDS-PAGE gel. The SDS page gels helped us to 
determine which elution fractions were used in the downstream experiments, and 
therefore, they were cleaned and concentrated by dialysis and centrifugation.  The gels 
provide a visual reference for which elution fractions contain the highest concentrations 
of protein.  As shown in FIG. 2A, for rOspC, fractions 3 through 17 contain the highest 
concentrations of proteins whereas elution fractions 3 through 12 had the higher 
concentration of rP66 (FIG. 2B). These fractions were then pulled and dialyzed to 
remove the Urea and imidazole used in the purification process, followed by 
concentration via centrifugation (Amicon system, Millipore). The fractions 5-10 were 
pulled, and concentrated for rOspC and fractions 3-8 were used for rP66. 
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Protein quantification 
After the protein was cleaned via dialysis and concentrated by filtration, the protein 
concentrations were determined by using the Pierce BCA Assay Kit.  The average 
concentrations of rP66 and rOspC were approximately 600 µg/mL and 500 µg/mL 
respectively.  FIG. 3 represents the standard curve obtained in the BCA assay for the 
quantification of both rP66 and rOspC.  This particular curve had a fitness value (r2) of 
0.999641. The concentrations of each protein were required to dilute them accordingly 
to coat the plates for the subsequent ELISA test.  A concentration of 5 µg /well was the 
standard concentration for this project.   
 
 
 
 
FIG 2. SDS-PAGE Gel. Recombinant OspC (A) and P66 (B) elution fractions were separated in a 
12% SDS-Page Gel and stained with Coomassie brilliant blue. Molecular weigh (MW) marker in kDa 
is represented on the left side of each gel (EZ-marker, Thermo-Fisher). PASN: Post Absorption 
SuperNatant (containing unbound proteins to Ni columns); FT: Flow Though wash, W1 and W2: 
Wash fractions; 1-26 are the different elution fractions isolated where the recombinant protein got 
purified in.  
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Immunoreactivity of dog serum to B. burgdorferi antigens 
After running ELISA tests using the different recombinant proteins (rP66 and rOspC) as 
well as the whole cell lysates, some discrepancies were found in between the IFA, the 
ELISA and Western blot (WB) tests. Out of the 30 IFA positive samples tested, 6 were 
diagnosed as negative using the ELISA and WB, which constitutes a 25% of false 
positive results when using the IFA diagnostic test. On the other hand, out of the 70 IFA 
negative samples studied, 42 were positive by ELISA and WB, which constitutes around 
60% of false negatives in the pool of samples studied. FIG 4 shows a representation of 
the various results obtained from the ELISA test and FIG 5 represents various results 
obtained from the Western Blots.   
 
 
 
 
FIG 3.: BCA Assay Standard Curve. 
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FIG. 4 ELISA Plates. Plates after incubating with different dog sera and were 
coated with rP66 (A), rOspC (B) and BB whole cell lysates (C).  
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The ELISA and Western Blots had very similar results and are much more accurate than 
the IFA. The results of all three tests were analyzed using STATA 11 to determine 
which combination of test will provide better diagnostic of Lyme disease in dogs.  FIG 
6A represents the correlations of the positive and negative samples when tested by IFA 
and ELISA. The ROC model was used to determine an accurate cut off value for the 
ELISA test. Figure 6B,C and D display the ROC curves for the three borrelial antigens.  
The statistical test of ROC areas found no significant evidence of a difference between 
the three antigens (p value = .16).  Nevertheless, the percent of correct diagnosis is 
below 70% in all cases, maintaining a 30% of misdiagnosis when using the 101 samples 
tested by ELISA thus far. 
 
The same type of statistical analysis was done using the 80 samples tested by WB. 
Figure 7A represents the antibody levels of the positive and negative samples when 
tested by WB. The ROC model was used to determine an optimum cut off value for the 
WB test.  Figure 7B,C and D display the ROC curves for the three borrelial antigens.  
 
 
FIG 5 Western Blot Results. Representative immunoblot strips from animals that were 
positive for both IFA and Western blot (+/+), negative for both (-/-), and positive for one 
or the other (+/-; -/+). The commercially available human LD IgG kit was purchased and 
adapted for dog serum samples.  
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The statistical test of ROC areas found no significant evidence of a difference between 
the three antigens (p value = .86). Moreover, when determining cut off values for the 
ELISA test, all three antigens provided values that will correctly diagnose 70 to 78% of 
the cases and will improve with the testing of more samples.  Consequently, P66 gave 
similar results to those observed when using either whole cell lysates or rOspC and 
therefore we suggest that P66 can be used as a potential new antigen for the development 
of a competitive ELISA for the diagnosis of LD in veterinary medicine regardless of the 
stage of infections in the tested animals.  
 
 
A)        B) 
          
C)       D) 
      
 
FIG 6. OD cut off determination based off of ELISA and IFA. OD cut offs based on both tests (A). Plot of 
ODs Cut offs based on P66  (B) Cut offs based on OspC (C) Cut offs based on BB (D). 
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Furthermore, we mapped the canine LD cases studied as well as the cumulative human 
LD cases from 2000-2010. In FIG.8A, we observed that the canine LD distribution in 
Texas is similar to that observed in humans (FIG. 8B) when using the same methodology 
for diagnostics (ELISA followed by Immunoblot assay). Moreover, the utilization of 
ELISA and Immunoblot allows a more sensitive diagnostics that results in a better 
mapping of the current canine LD cases in TX during the last trimester in the year 2011 
and the beginning of year 2012.  
A)        B) 
          
C)       D) 
         
 
FIG 7. OD cut off determination based off of ELISA and IFA.  OD cut offs based on both tests (A) Plot of 
ODs Cut offs based on P66 (B) Cut offs based on OspC (C) Cut offs based on BB (D) 
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B) 
 
 
FIG.8. Distribution of human and canine LD in Texas. Cumulative human LD cases 
reported to CDC are represented in figure A (Data obtained through the Texas 
Department of State Health Servises). The counties with highest incidences of human LD 
were Travis with 127 cases reported followed by Dallas (125 cases) and Tarrant (118 
cases). Canine LD cases analyzed by TVMDL by IFA and reanalyzed by our laboratory 
by means of ELISA and IB are represented in figure B. These results suggest that sero-
surveillance of dogs and other species together with the analysis of sampled ticks will 
help determining the localization of areas of high risk of LD. 
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
Many researchers have concluded that companion animals (dogs in particular) are very 
useful sentinels for the assessment of LD in a given area (9, 13, 17, 18, 20, 24).  The 
maps generated in this study are a supportive evidence of this idea by showing the 
similar patterns of the disease in both humans and dogs in the state of Texas where the 
distribution of LD has not been studied until now.  On the other hand, our study has been 
very helpful in order to determine which of the testing methods is most accurate for the 
diagnostics of LD in Texas. This study allows us to conclude that IFA is not an 
appropriate diagnostic tool for Lyme disease in veterinary medicine due to the high ratio 
of miss diagnostic observed in the population studied (false positive and false negative). 
This result was observed by others in different regions of Europe and the US where LD 
is endemic (12, 18, 24). Therefore our result support the fact that LD in Texas might be 
under reported due to lack of good diagnostic tools and awareness in the human and 
veterinary medicine community.  
 
The CDC currently recommends using a two-tier approach when testing for LD 
serologically in humans; usually an initial ELISA or IFA followed by WB.  Seeing this 
as a successful testing method used in human diagnostics, it should be as effective in 
veterinary diagnostics (6). After comparing the IFA tests with the confirmatory Western 
Blots and ELISAs, we have observed that IFA gives many false negatives (66%) as well 
as false positives (25%).  The statistical analysis of all three testing methods (IFA, 
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Western Blot, and ELISA) led us to the conclusion that P66 is a good candidate for the 
development of a Competitive ELISA due to its sensitivity when measuring the antibody 
levels in dog serum sample.  OspC and BB lysate are both good indicators; however, 
OspC antibodies are mostly representative of an early infection and therefore aren’t as 
accurate (8).  
 
The development of this test will result in better diagnostics to be used in veterinary 
medicine to detect vector borne zoonotic diseases, having a high impact not only on 
animal but also on human health. Specifically, with better diagnostic tests, the efficacy 
of available treatments in both animal and human medicine will increase considerably. 
As observed in the preliminary maps generated with only 80 dog serum samples we can 
start seeing a distribution of veterinary LD very similar to that observed in the human 
population, with the added value that the animal LD is closer to the natural areas where 
the infection happens. Additionally, by using the same diagnostic tools in both human 
and veterinary medicine comparative studies, more accurate predictions of distribution 
and dissemination of the disease in areas where this disease is not well understood can 
be made. Consequently, when using the same techniques, we observed that most of the 
human and animal cases are reported around the big metropolitan areas of Austin, Dallas 
Fort Worth and Houston and along the border of Mexico. This observation might be due 
to the fact that both MDs and DVMs in those urban metropolitan areas are more aware 
of the disease than those practicing in rural areas.  Consequently, by developing a 
method that can be used in surveillance programs we can monitor the levels of LD in the 
environment, develop mathematical models and predict when the disease can emerge in 
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different areas. By understanding the distribution of the disease in companion animals as 
well as in wild life we can better understand the maintenance of the enzootic cycle of LD 
(7).  
 
This thesis encompasses the first steps towards the development of a pan-specific test to 
be used in such surveillance programs. Together with the immune-reactivity of Texan 
dog serum, we are also studying the sero-reactivity of white tail deer are horses 
throughout the state. These preliminary studies will help us to understand the immune-
reactivity of these animals in Texas and what antigens are best to use in this state. Taken 
together all the approaches and the results of the different direct ELISAS we will be able 
to outline the basic conditions to start the standardization of the pan-specific test 
proposed in this thesis.  
 
In addition to this study, our laboratory is collecting ticks from different areas in Texas 
in order to correlate the presence of LD in human and animals to the areas in the state 
that might be maintaining the pathogen in its enzootic cycle, and can be consider as the 
areas with high risk for infection with the disease. A diagnostic test that is not host 
species specific will be of great value when establishing surveillance programs, since it 
avoids the generation of reagents for each specific animal species to be monitored, thus 
making the diagnosis of LD an easier process. The methodology we are trying to 
develop will decrease the amount of errors that occur from the current testing method.  
This project is still a work in progress.  Due to time constraints we have only been able 
to test 100 samples of dog serum thus far, making it our animal model.  However, other 
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animal (cattle, horses and WTD) sera will be analyzed following the same methodology.  
Nevertheless, this project has helped prove that Western Blot and ELISA are the better 
diagnostic tools, not only for human, but also for veterinary medicine. By testing a larger 
number of samples and a variation of species, this testing method will improve 
diagnostic tests and improve the surveillance of Lyme disease in states where the 
distribution of the disease and the maintenance of its enzootic cycles is not very well 
understood. 
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